The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.
Melnichenko G.A.
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia, Moscow, Russia;
Endocrinology Research Center, Ministry of Health of Russia, Moscow, Russia
Belaia Zh.E.
FGU Éndokrinologicheskiĭ nauchnyĭ tsentr Minzdravsotsrazvitiia Rossiĭskoĭ Federatsii, Moskva
Rozhinskaia L.Ia.
FGU Éndokrinologicheskiĭ nauchnyĭ tsentr, Moskva
Toroptsova N.V.
Research Institute of Rheumatology n.a. V.A. Nasonova, Moscow, Russia
Alekseeva L.I.
Research Institute of Rheumatology n.a. V.A. Nasonova, Moscow, Russia
Biryukova E.V.
Moscow State University of Medicine and Dentistry n.a. A.I. Evdokimov, Moscow, Russia
Grebennikova T.A.
Endocrinology Research Center, Moscow, Russia
Dzeranova L.K.
ndokrinologicheskiĭ nauchnyĭ tsentr Minzdrava RF, Moskva
Dreval' A.V.
Moskovskiĭ oblastnoĭ nauchno-issledovatel'skiĭ klinicheskiĭ institut im. M.F. Vladimirskogo
Zagorodniy N.V.
Central Research Institute of Traumatology and Orthopedics n.a. N.N. Priorov, Moscow, Russia;
Peoples’ Friendship University of Russia, Moscow, Russia
Il'in A.V.
FGU Éndokrinologicheskiĭ nauchnyĭ tsentr, Moskva
Kriukova I.V.
Moskovskiĭ oblastnoĭ nauchno-issledovatel'skiĭ klinicheskiĭ institut im. M.F. Vladimirskogo
Lesnyak O.M.
North-Western State Medical University n.a. I.I. Mechnikov, St. Petersburg, Russia
Mamedova E.O.
FGBU "ndokrinologicheskiĭ nauchnyĭ tsentr" Minzdrava RF, Moskva
Nikitinskaya O.A.
Research Institute of Rheumatology n.a. V.A. Nasonova, Moscow, Russia
Pigarova E.A.
FGU Éndokrinologicheskiĭ nauchnyĭ tsentr Minzdravsotsrazvitiia RF, Moskva
Rodionova S.S.
Central Research Institute of Traumatology and Orthopedics n.a. N.N. Priorov, Moscow, Russia
Skripnikova I.A.
National Research Center for Preventive Medicine, Moscow, Russia
Tarbaeva N.V.
Endocrinology Research Center, Moscow, Russia
Farba L.Ya.
Municipal Clinical Hospital No 13, Moscow, Russia
Tsoriev T.T.
The National Research Center for Endocrinology, Moscow, Russia
Chernova T.O.
FGBU "ndokrinologicheskiĭ nauchnyĭ tsentr" Minzdrava RF
Yureneva S.V.
Acad. V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia, Moscow, Russia
Yakushevskaya O.V.
Research Center for Obstetrics, Gynecology, and Perinatology, Moscow, Russia
Dedov I.I.
Endocrinology Research Centre
Russian federal clinical guidelines on the diagnostics, treatment, and prevention of osteoporosis
Journal: Problems of Endocrinology. 2017;63(6): 392‑426
Views: 21292
Downloaded: 1562
To cite this article:
Melnichenko GA, Belaia ZhE, Rozhinskaia LIa, et al. . Russian federal clinical guidelines on the diagnostics, treatment, and prevention of osteoporosis. Problems of Endocrinology.
2017;63(6):392‑426. (In Russ.)
https://doi.org/10.14341/probl2017636392-426
Screening using the Fracture Risk Assessment Tool (FRAX) is recommended in all postmenopausal woman and mеn over 50 (A1) in order to identify individuals with high probability of fractures. It is recommended to diagnose osteoporosis and start treatment in patients with fragility fracture of large bones of the skeleton and/or high individual probability of major fragility fractures (FRAX) and/or detected decrease in bone mineral density (BMD) up to –2.5 T-score as assessed by DXA in the femoral neck and/or lumbar vertebrae (A1). Patients with back pain, lifetime height loss of 4 cm or height loss of 2 cm since a previous medical examination, those who receive glucocorticoids, patients with long lasting decompensated type 2 diabetes mellitus, or those receiving insulin therapy, as well as patients who were previously diagnosed with fragility fractures at the other sites are advised to underwent standard lateral X-ray imaging of the spine (Th4—L5) in order to verify the presence of compression vertebral fractures (B1). Dual-energy X-ray absorptiometry (DXA) is recommended for individuals whose 10-year probability of major osteoporotic fracture (FRAX) falls within the medium risk group (B1). It is recommended to include the trabecular bone score (TBS) the FRAX algorithm in order to improve the sensitivity of this method (B1). Laboratory testing is recommended for the differential diagnosis with other causes of increased skeletal fragility in all patients with newly diagnosed osteoporosis and when previously prescribed antiosteoporostic treatment was ineffective (B1). Bisphosphonates (BPs), antibodies to receptor activator of nuclear factor kappa-beta ligand (RANKL) (denosumab), or parathyroid hormone analogue (teriparatide) are equally recommended to prevent fragility fractures and increase BMD in patients with osteoporosis (A1). Denosumab is also recommended to prevent BMD loss and fractures in females receiving aromatase inhibitors therapy for breast cancer and males with prostate cancer receiving hormone-deprivation therapy and having no bone metastases (A1). Since teriparatide has the anabolic effect, it is recommended as the first line treatment in patients with severe osteoporosis having history of vertebral fractures, in the individuals with very high risk of fragility fractures, or in the cases when antiresorptive treatment was ineffective (B1). All medications for treatment of osteoporosis are recommended in combination with calcium and vitamin D supplements (A1).
Authors:
Melnichenko G.A.
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia, Moscow, Russia;
Endocrinology Research Center, Ministry of Health of Russia, Moscow, Russia
Belaia Zh.E.
FGU Éndokrinologicheskiĭ nauchnyĭ tsentr Minzdravsotsrazvitiia Rossiĭskoĭ Federatsii, Moskva
Rozhinskaia L.Ia.
FGU Éndokrinologicheskiĭ nauchnyĭ tsentr, Moskva
Toroptsova N.V.
Research Institute of Rheumatology n.a. V.A. Nasonova, Moscow, Russia
Alekseeva L.I.
Research Institute of Rheumatology n.a. V.A. Nasonova, Moscow, Russia
Biryukova E.V.
Moscow State University of Medicine and Dentistry n.a. A.I. Evdokimov, Moscow, Russia
Grebennikova T.A.
Endocrinology Research Center, Moscow, Russia
Dzeranova L.K.
ndokrinologicheskiĭ nauchnyĭ tsentr Minzdrava RF, Moskva
Dreval' A.V.
Moskovskiĭ oblastnoĭ nauchno-issledovatel'skiĭ klinicheskiĭ institut im. M.F. Vladimirskogo
Zagorodniy N.V.
Central Research Institute of Traumatology and Orthopedics n.a. N.N. Priorov, Moscow, Russia;
Peoples’ Friendship University of Russia, Moscow, Russia
Il'in A.V.
FGU Éndokrinologicheskiĭ nauchnyĭ tsentr, Moskva
Kriukova I.V.
Moskovskiĭ oblastnoĭ nauchno-issledovatel'skiĭ klinicheskiĭ institut im. M.F. Vladimirskogo
Lesnyak O.M.
North-Western State Medical University n.a. I.I. Mechnikov, St. Petersburg, Russia
Mamedova E.O.
FGBU "ndokrinologicheskiĭ nauchnyĭ tsentr" Minzdrava RF, Moskva
Nikitinskaya O.A.
Research Institute of Rheumatology n.a. V.A. Nasonova, Moscow, Russia
Pigarova E.A.
FGU Éndokrinologicheskiĭ nauchnyĭ tsentr Minzdravsotsrazvitiia RF, Moskva
Rodionova S.S.
Central Research Institute of Traumatology and Orthopedics n.a. N.N. Priorov, Moscow, Russia
Skripnikova I.A.
National Research Center for Preventive Medicine, Moscow, Russia
Tarbaeva N.V.
Endocrinology Research Center, Moscow, Russia
Farba L.Ya.
Municipal Clinical Hospital No 13, Moscow, Russia
Tsoriev T.T.
The National Research Center for Endocrinology, Moscow, Russia
Chernova T.O.
FGBU "ndokrinologicheskiĭ nauchnyĭ tsentr" Minzdrava RF
Yureneva S.V.
Acad. V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia, Moscow, Russia
Yakushevskaya O.V.
Research Center for Obstetrics, Gynecology, and Perinatology, Moscow, Russia
Dedov I.I.
Endocrinology Research Centre
List of references:
Close metadata
Email Confirmation
An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.
Email Confirmation
Log in to the site using your account in one of the services
We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.